EXPANDED ACCESS PROGRAM: SAFETY OF ERYTHROCYTES ENCAPSULATING L-ASPARAGINASE (GRASPA®) IN COMBINATION WITH POLYCHEMOTHERAPY IN PATIENTS UNDER 55 YEARS OLD WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AT RISK TO RECEIVE OTHER FORMULATION OF ASPARAGINASE: